About ReGelTecAdmin

This author has not yet filled in any details.
So far ReGelTecAdmin has created 8 blog entries.

ReGelTec Presents Early Feasibility Study at ASSR Annual Meeting

By |2021-02-23T17:30:16+00:00February 23rd, 2021|

ReGelTec, Inc., a clinical stage medical device company developing HYDRAFIL™, a percutaneous treatment for chronic low back pain, announced the presentation of Early Feasibility Study (EFS) results by Dr Alfonso Spath at the American Society of Spine Radiology annual meeting that took place February 19-21, 2021.

ReGelTec, Inc., a Rowan Innovation Venture Fund investment, receives FDA breakthrough designation

By |2021-01-18T17:43:28+00:00December 18th, 2020|

ReGelTec, Inc., a medical device company developing a treatment for chronic low back pain, has received breakthrough device designation for its HYRDAFIL System from the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA).

ReGelTec Successfully Treats First Eleven Chronic Low Back Pain Patients with HYDRAFIL™

By |2021-01-18T17:50:39+00:00October 14th, 2020|

ReGelTec, Inc., a medical device company developing a percutaneous treatment for chronic low back pain, announced today that eleven patients with degenerative disc disease have been enrolled in the Company’s Early Feasibility Study in Barranquilla, Colombia.

Regeltec chooses Colombia and Bioaccess™ for the first-in-human clinical trial of its HYDRAFIL system

By |2021-01-11T18:57:37+00:00October 19th, 2019|

ReGelTec, Inc., a Baltimore-based medical device startup company that is developing the next generation of minimally invasive spinal implants for lower back pain and degenerative disc disease, has chosen Colombia and bioaccess™ as its CRO to conduct the first-in-human clinical trial of its HYDRAFIL System.

Go to Top